Alliance Pharma, a bioanalytical research organization and an Ampersand portfolio company, has agreed to acquire DDS, a bioanalytical business unit of LGC.

The combined firm will enable its clients to benefit from its capabilities in bioanalytical science.

KKR is investing in Alliance and DDS through KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on health care companies.

Euan O’Sullivan, CEO, LGC, said: “I am proud of the scientific and commercial achievements delivered by the DDS business over the years, supporting customers in their mission to develop new medicines and products to improve the quality of life. I am confident that as part of the Alliance organization, the DDS team will be well positioned for on-going success as part of a global business focused on bioanalytical and materials sciences activities.”